In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations. Yet one company ...
Keep Reading →
July 19 - News
In today’s information age, people like to be active, and follow their investments closely.
Keep Reading →
July 15 - News
On Friday we saw several stock-moving upgrades in preparation of a long week of earnings; here are four that really caught my eye.
Keep Reading →
July 13 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
July 3 - News
In April of last year I decided that the boundaries of financial metrics no longer mattered to me, and I embarked on creating my own unique index, dubbed the TMFULOI, to examine...
Keep Reading →
July 3 - News
The entire biotech space is moving higher in response to the bid for Onyx Pharmaceuticals, especially those with Orphan blockbusters.
Keep Reading →
July 2 - News
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Keep Reading →
June 27 - News
Earnings per share, or EPS, shows the rate at which a company has grown its profitability. EPS growth is a good fundamental indicator of the future prospects of a company.
Keep Reading →
June 27 - News
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) got crushed with a downgrade from Credit Suisse that led to a 6.3% loss on Monday.
Keep Reading →
June 25 - News
Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions and Roche's vaccine market share.
Keep Reading →
June 21 - News
Anticipation of tomorrow's Federal Reserve open market meeting is building, and the indication from investors thus far, following a second straight day of big gains in the broad...
Keep Reading →
June 19 - News
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
Keep Reading →
June 18 - News
Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions.
Keep Reading →
June 18 - News
Biotechnology's a volatile sector that can intimidate many investors, but it's also a landscape of stocks that can reward portfolios with giant gains.
Keep Reading →
June 17 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike– every time there’s a slight pullback the stock shoots higher.
Keep Reading →
June 17 - News
While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry...
Keep Reading →
June 13 - News
Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE:MRK) is no exception. Merck & Co., Inc.
Keep Reading →
June 12 - News
Everyone has had a friend at school who was asthmatic. Life is not easy for the chronic asthmatic.
Keep Reading →
June 12 - News
It hasn't happened nearly as often as optimists would like to see in recent weeks, but improving economic data matched the move higher in the broad-based S&P 500 today, and gave...
Keep Reading →
June 7 - News
To the average investor, there are dozens of indicators market participants can use to analyze the equity markets.
Keep Reading →
June 3 - News
For many companies, rising to become part of the S&P 500 (S&P Indices:.INX) represents the pinnacle of their achievement.
Keep Reading →
June 3 - News
Aegerion Pharmaceuticals, Inc.
Keep Reading →
May 31 - News
Some stocks seem to have all the luck, offering the best of both worlds.
Keep Reading →
May 30 - News
I have jokingly referred to Amgen, Inc. (NASDAQ:AMGN) in the past as a "senior citizen" of biotech. The company was founded 33 years ago, making Amgen, Inc.
Keep Reading →
May 24 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) peaked on May 14 with a price of $283.99, and has since pulled back to its current price of $260.
Keep Reading →
May 23 - News
Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer (as a first-line and second-line treatment), metastatic HER2-negative breast...
Keep Reading →
May 19 - News
Editor's Note: Related Tickers: First Solar, Inc.
Keep Reading →
May 13 - News
On March 28, more than three weeks after the Dow Jones Industrial Average (Dow Jones Indices:.DJI) managed to climb to a new all-time record high, the S&P 500 finally followed...
Keep Reading →
May 12 - News
Investments in biotechnology by the average investor tend to deliver hit or miss returns over time.
Keep Reading →
May 8 - News
Wall Street had a great week. The Dow topped 15,000. The S&P 500 also notched a record high. But few stocks blew the doors off like those of these three biotech companies.
Keep Reading →
May 4 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
May 2 - News
One of the nice things about owning biotech companies is the large number of acquisitions in the sector.
Keep Reading →
April 30 - News
To the average investor, there are plenty of methods shareholders can use to monitor the equity markets.
Keep Reading →
April 26 - News
Heart disease kills nearly 600,000 Americans every year, making it the nation's No. 1 cause of death, according to the Centers for Disease Control and Prevention.
Keep Reading →
April 24 - News
I don't know about you, but I'm pretty stoked for the NFL draft this Thursday.
Keep Reading →
April 22 - News
Two high-flying biotech stocks of late are NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) .
Keep Reading →
April 16 - News
Biotechs offer the possibility of monster returns. Overnight doubles aren't out of the question.
Keep Reading →
March 28 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News
With the Nasdaq Biotechnology Index hitting record highs, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat about whether we're in...
Keep Reading →
March 22 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 5 - News
Typically, it doesn't take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst's remarks, sometimes it's caused by earnings...
Keep Reading →
February 12 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) said Monday that it got a notice from its partner Sanofi SA (NYSE:SNY) saying that the pharma intends to buy additional shares of the...
Keep Reading →
February 12 - News
With no major health-care conferences on the docket this week, and the Food and Drug Administration ruling two days early on Celgene Corporation (NASDAQ:CELG)'s multiple myeloma...
Keep Reading →
February 11 - News
On October 7, 2007 the Dow Jones closed at a record 14,164.53.
Keep Reading →
February 1 - News
Last year was a pretty good one for stockholders in Sanofi SA (NYSE:SNY), and the indications are that this year could be the same.
Keep Reading →
January 15 - Stock Analysis
Mutual funds and exchange-traded funds (ETF) that focuses on dividend stocks can be good sources of ideas about attractive high-yield or high dividend-growth plays.
Keep Reading →
November 1 - Dividend Stocks
